Please assess the completion status of the following clinical trial:

Trial Title: Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Adult patients aged 18 to 85 will be eligible for inclusion in this study if all of the following criteria apply:~1. Willing to provide written informed consent~2. Confirmed diagnosis (biopsy-proven) of intermediate- and high-risk NMIBC~3. Two to four weeks following complete tumor resection~4. Candidate for BCG induction therapy based on CUA clinical guidelines~5. Subjects must not be pregnant, lactating, or actively trying to become pregnant, Subjects who are premenopausal and of childbearing potential must have a negative pregnancy test at Screening (serum) and at Day 0 (urine) and must use a medically acceptable and effective method of birth control for the duration of the study, which can include:~   1. Having a male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject~  2. Use of double-barrier methods of contraception; condoms with the use of caps (with spermicide) and intra-uterine devices are acceptable~  3. Use of hormonal contraceptives (oral, depots, patches, etc.) with double-barrier methods of contraception as outline above~  4. True abstinence: When this is in line with the preferred and usual lifestyle of the subject (period abstinence \[eg, calendar, ovulation, symptothermal, post-ovulation methods\] and withdrawal are not acceptable methods of contraception)~Exclusion Criteria:~1. Contraindications to BCG therapy~2. Solitary tumors except pT1 high grade~3. Tumor stage ≥ T2~4. Previous BCG or chemotherapy instillation~5. Carcinoma in situ and variant histology of urothelial carcinoma~6. Subjects with concurrent (at Screening), urinary tract infections (positive dipstick for urinary tract infection and abnormal microscopic evaluation, signs and symptoms)~7. Unevaluated urinary retention, Post void residual (PVR) urine volume \> 150 ml~8. Diagnosis of dementia~9. Any concurrent condition or any clinically significant abnormality on the screening physical examination, laboratory tests, which, in the opinion of the Investigator, may affect the interpretation of efficacy or safety data, or which otherwise contraindicates participation in a clinical study with PPS.~   1. Hypersensitivity to PPS or any of its ingredients~  2. History of clinically significant drug hypersensitivity.~  3. Clinically significant or unstable, endocrine, hepatic, renal, immunologic, or heart disease~  4. Patients at increased hemorrhagic risk due to unstable disease course (ulcerative GI lesions, aneurysms, internal or external hemorrhoids, thrombocytopenia, hemophilia, polyps or diverticulae).~10. Use of any pharmacologic agent used to treat symptoms of LUTS~11. Participation in a clinical study within the month prior to screening, or exposure to an investigational drug which has not washed out since the last administration prior to screening~12. In the opinion of the Investigator, is at risk of non-compliance with study procedures, or cannot read, understand, or complete study-related materials, particularly informed consent~13. Participation in any clinical study of an investigational drug that may affect urinary function within 1 months prior to screening~14. Severe renal impairment (estimated glomerular filtration rate \< 30 mL/min/1.73m2)~15. Severe hepatic impairment (Child-Pugh B or greater)~16. You are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Pentosan Polysulfate Na 100Mg Cap (Type: EXPERIMENTAL): Drug intervention of Pentosan Polysulfate Na 100Mg Cap (ELMIRON) thrice daily PO for 6 weeks, after meeting the eligibility criteria during the the two-week Screening period.
- Placebo oral capsule (Type: PLACEBO_COMPARATOR): Participants will receive Placebo oral capsule, similar to (ELMIRON 100mg) thrice daily PO for 6 weeks, , after meeting the eligibility criteria during the the two-week Screening period.

Based on this trial design, predict the completion outcome and termination type (if applicable).